Clinical Trial Update: AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib [Phase 2]

View source ↗

Summary

This document reports the completion of a Phase 2 trial of AMG 386 in combination with sorafenib for first-line advanced renal cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• AMG-386 (trebananib)
• Sorafenib (Sorafenib)

Snippet

Sponsor: Amgen | Conditions: Advanced Renal Cell Carcinoma | Phase 2 | Status: COMPLETED